On September 24, 2024, the Association of Cannabinoid Specialists (www.cannaspecialists.com) hosted a paneled event surrounding the topic of policy and rescheduling, and what it means for patients and clinicians.

Recently President and Founder of the Association of Cannabinoid Specialists, Jordan Tishler, MD, was invited to participate in a panel at the Cannabis Regulators Association (CANNRA) 2024 External Stakeholder Meeting in Minneapolis, MN.

Recently, the Delaware House of Representatives, following ideas from Washington D.C., passed a law to do two things:  (1) remove the list of qualifying conditions from their medical cannabis laws, and (2) allow people over the age of 65 to “self-certify” that they need marijuana for medical purposes.

Dear Madam/Sir: I write to you to support the petitions before you to include anxiety, depression, and insomnia as qualifying conditions for medical cannabis treatment in Hawai’i.

Dear Members of the Joint Committee:

As one of the senior cannabis physicians in the Commonwealth of Massachusetts, President of the Association of Cannabis Specialists, Board Member of the Massachusetts Patient Advocacy Alliance, and former VA physician I wish to convey some very specific concerns regarding House Bill 4274. Despite vocal advocacy by a few veterans, this bill is not in the interests of veterans or other patients.

In an editorial in JAMA, Dr. Nathaniel Morris, a recent Stanford graduate, laments that even in California where medical cannabis has been available since 1996, no medical education on cannabis was provided to him during medical school or residency.

The currently posed question of when or whether the embargoed oil cartridges can be released for sale has at least two separate issues embedded. First is the question of the safety of these particular cartridges, and the second is the safety of any such cartridges that use current technology. Both of these questions would reasonably need to be affirmed prior to sales.

Since the inception of medical cannabis legalization in California in 1996, physicians have only been able to write a “recommendation”. This was intended, at that time, to keep the practitioners out of trouble with the government by providing only a document stating that the benefits likely outweighed the risks. 

The Medical Cannabis Research Advocacy Alliance (MCRAA) appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry; Availability 85 FR 44305 (July 22, 2020).

To Whom It May Concern at the Wall Street Journal:

We write to you to express a concern over a recent ½ page advertisement in the Journal.